Incyte Gains as Melanoma Combo Sees Success in Early-Stage Trial

Incyte Corp. rose to its highest level since January as one of its experimental drug yielded positive results in an early-stage trial when used in combination therapy for a form of skin cancer.

About 74 percent of patients with advanced melanoma who received Incyte’s epacadostat in combination with Merck & Co.’s Keytruda saw their disease stabilize or improve, cialis and the treatment was well tolerated. The shares gained 4.6 percent to $93.65 at 12:40 p.m. in New York, there after earlier reaching $95.39.

Melanoma, the deadliest form of skin cancer, kills about 10,130 people in the U.S. annually, according to the Skin Care Foundation, and doctors are looking for better treatments for severe cases. Incyte’s results, reported Wednesday in a statement, show that an additional patient responded to the treatment since an earlier release of data. That indicates it may compare favorably with Bristol Myers-Squibb Co.’s combination of its Opdivo and Yervoy drugs for melanoma, said Sam Fazeli, an analyst with Bloomberg Intelligence.

Read Full Article Here >>